albumin-bound paclitaxel + cisplatin + pd-1 monoclonal antibody

This is a **combination regimen** consisting of **albumin-bound paclitaxel (nab-paclitaxel), cisplatin, and a PD-1 monoclonal antibody**. Albumin-bound paclitaxel is a nanoparticle, solvent-free formulation of paclitaxel designed to reduce toxicities associated with conventional solvents and improve tumor delivery[4]. Cisplatin is a platinum-based chemotherapeutic agent. PD-1 monoclonal antibodies (such as pembrolizumab, nivolumab, camrelizumab, tislelizumab, or similar) block the programmed cell death protein 1 (PD-1) checkpoint, restoring T cell–mediated immune responses against tumor cells. The combination is investigated primarily as a **first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck, including hypopharyngeal and laryngeal squamous cell carcinoma**, as well as other solid tumors[1]. Mechanistically, this regimen combines cytotoxic chemotherapy with immune checkpoint inhibition to enhance anti-tumor efficacy[1][4].